Transcode Therapeutics: Funding, Investors & Team (Oct 2026)
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor types and has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.
Transcode Therapeutics has raised $9.4M across 3 funding rounds on record, the most recent an undisclosed round of $6.0M announced in Apr 2026.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Transcode Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Transcode Therapeutics Funding Rounds
Transcode Therapeutics raised $2.3M in a Grant announced in Aug 2021.
10 months later, a Grant of $1.1M was announced in Jun 2022.
3.8 years later, an undisclosed round of $6.0M was announced in Apr 2026.
Transcode Therapeutics Founders and Leadership Team
Contact details for the Transcode Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Transcode Therapeutics Funding Compared to Other Biotechnology Startups
Transcode Therapeutics' latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Transcode Therapeutics in Biotechnology and Boston
Companies Similar to Transcode Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Transcode Therapeutics Funding FAQs
What does Transcode Therapeutics do?
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor types and has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.
How much funding has Transcode Therapeutics raised?
Transcode Therapeutics has raised $9.4M across 3 rounds on record. The most recent is an undisclosed round of $6.0M announced in Apr 2026.
When did Transcode Therapeutics last raise funding?
Transcode Therapeutics' most recent funding round on record is an undisclosed round of $6.0M, announced in Apr 2026.
Who founded Transcode Therapeutics?
FundedIQ lists Philippe Calais (Founder) at Transcode Therapeutics.
Who is the CEO of Transcode Therapeutics?
Michael Dudley is listed as CEO at Transcode Therapeutics.
Where is Transcode Therapeutics headquartered?
Transcode Therapeutics is based in Boston, Massachusetts, United States.
How many employees does Transcode Therapeutics have?
Transcode Therapeutics is in the 1-10 employee band.
How does Transcode Therapeutics' funding compare to other Biotechnology startups?
Transcode Therapeutics' latest round of $6.0M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Transcode Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Transcode Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.